Dirk Jaeger

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

Tomasz M. Beer, Eugene D. Kwon, Charles G. Drake et al. · Journal of Clinical Oncology · 2016 · 742 citations · Full text

Pharmacotherapy, Immunotherapeutics, Immunotherapy +16

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

Padmanee Sharma, Margaret K. Callahan, Petri Bono et al. · The Lancet Oncology · 2016 · 676 citations · Full text

Urology, Genitourinary Cancer, Medicine +7

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

Yelena Y. Janjigian, Johanna C. Bendell, Emiliano Calvo et al. · Journal of Clinical Oncology · 2018 · 613 citations · Full text

Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients

Niels Halama, Inka Zoernig, Anna Berthel et al. · Cancer Cell · 2016 · 486 citations · Full text

Cancer Immunosurveillance, Anti-ccr5 Therapy, Medicine +10

Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy

Niels Halama, Sara Michel, Matthias Kloor et al. · Cancer Research · 2011 · 424 citations

Immunology, Pathology, High Densities +16